Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma

Krittiya Korphaisarn; Van Morris; Jenifer S. Davis; Michael J. Overman; David R. Fogelman; Bryan K. Kee; Arvind Dasari; Kanwal P.S. Raghav; Imad Shureiqi; Metha Trupti; Robert A. Wolff; Cathy Eng; David G. Menter; Stanley Hamilton; Scott Kopetz

doi:10.1038/s41416-019-0548-9

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma

Krittiya Korphaisarn, Van Morris, Jenifer S. Davis, Michael J. Overman, David R. Fogelman, Bryan K. Kee, Arvind Dasari, Kanwal P.S. Raghav, Imad Shureiqi, Metha Trupti, Robert A. Wolff, Cathy Eng, David G. Menter, Stanley Hamilton, Scott Kopetz

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Background: Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations and outcomes of SRCC. Methods: Medical records of metastatic CRC (mCRC) patients whose tumours were evaluated by NGS analysis were reviewed. SC-mCRC were classified into two groups: SRCC (>50% signet ring cells) and adenocarcinoma (AC) with SC component (≤50% signet ring cells). Results: Six hundred and sixty-five mCRC patients were included. Of the 93 mCRC cases with SC features, 63 had slides for review. Of those 63 cases, 35 were confirmed SRCC, and 28 were AC with SC component. Compared with AC group, KRAS and PIK3CA mutations (mts) were found in only 11% (OR: 0.13) and 3% (OR: 0.15) of SRCC cases, respectively. In contrast to the 44% rate of APC mts in AC group, only 3% of SRCC patients had APC mts (OR = 0.04). Conclusions: SRCC has distinct molecular features, including low rates of KRAS, PIK3CA and APC mts. Further study to identify activation pathways and potential therapeutic targets are needed.

Original language	English (US)
Pages (from-to)	505-510
Number of pages	6
Journal	British journal of cancer
Volume	121
Issue number	6
DOIs	https://doi.org/10.1038/s41416-019-0548-9
State	Published - Sep 10 2019

ASJC Scopus subject areas

Oncology
Cancer Research

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1038/s41416-019-0548-9

Cite this

Korphaisarn, K., Morris, V., Davis, J. S., Overman, M. J., Fogelman, D. R., Kee, B. K., Dasari, A., Raghav, K. P. S., Shureiqi, I., Trupti, M., Wolff, R. A., Eng, C., Menter, D. G., Hamilton, S., & Kopetz, S. (2019). Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. British journal of cancer, 121(6), 505-510. https://doi.org/10.1038/s41416-019-0548-9

Korphaisarn, K, Morris, V, Davis, JS, Overman, MJ, Fogelman, DR, Kee, BK , Dasari, A , Raghav, KPS, Shureiqi, I, Trupti, M, Wolff, RA, Eng, C, Menter, DG, Hamilton, S & Kopetz, S 2019, 'Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma', British journal of cancer, vol. 121, no. 6, pp. 505-510. https://doi.org/10.1038/s41416-019-0548-9

@article{15eaf81d99a24bb592040d8c9f04cd3c,

title = "Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma",

abstract = "Background: Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations and outcomes of SRCC. Methods: Medical records of metastatic CRC (mCRC) patients whose tumours were evaluated by NGS analysis were reviewed. SC-mCRC were classified into two groups: SRCC (>50% signet ring cells) and adenocarcinoma (AC) with SC component (≤50% signet ring cells). Results: Six hundred and sixty-five mCRC patients were included. Of the 93 mCRC cases with SC features, 63 had slides for review. Of those 63 cases, 35 were confirmed SRCC, and 28 were AC with SC component. Compared with AC group, KRAS and PIK3CA mutations (mts) were found in only 11% (OR: 0.13) and 3% (OR: 0.15) of SRCC cases, respectively. In contrast to the 44% rate of APC mts in AC group, only 3% of SRCC patients had APC mts (OR = 0.04). Conclusions: SRCC has distinct molecular features, including low rates of KRAS, PIK3CA and APC mts. Further study to identify activation pathways and potential therapeutic targets are needed.",

author = "Krittiya Korphaisarn and Van Morris and Davis, {Jenifer S.} and Overman, {Michael J.} and Fogelman, {David R.} and Kee, {Bryan K.} and Arvind Dasari and Raghav, {Kanwal P.S.} and Imad Shureiqi and Metha Trupti and Wolff, {Robert A.} and Cathy Eng and Menter, {David G.} and Stanley Hamilton and Scott Kopetz",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s), under exclusive licence to Cancer Research UK.",

year = "2019",

month = sep,

day = "10",

doi = "10.1038/s41416-019-0548-9",

language = "English (US)",

volume = "121",

pages = "505--510",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Signet ring cell colorectal cancer

T2 - genomic insights into a rare subpopulation of colorectal adenocarcinoma

AU - Korphaisarn, Krittiya

AU - Morris, Van

AU - Davis, Jenifer S.

AU - Overman, Michael J.

AU - Fogelman, David R.

AU - Kee, Bryan K.

AU - Dasari, Arvind

AU - Raghav, Kanwal P.S.

AU - Shureiqi, Imad

AU - Trupti, Metha

AU - Wolff, Robert A.

AU - Eng, Cathy

AU - Menter, David G.

AU - Hamilton, Stanley

AU - Kopetz, Scott

PY - 2019/9/10

Y1 - 2019/9/10

N2 - Background: Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations and outcomes of SRCC. Methods: Medical records of metastatic CRC (mCRC) patients whose tumours were evaluated by NGS analysis were reviewed. SC-mCRC were classified into two groups: SRCC (>50% signet ring cells) and adenocarcinoma (AC) with SC component (≤50% signet ring cells). Results: Six hundred and sixty-five mCRC patients were included. Of the 93 mCRC cases with SC features, 63 had slides for review. Of those 63 cases, 35 were confirmed SRCC, and 28 were AC with SC component. Compared with AC group, KRAS and PIK3CA mutations (mts) were found in only 11% (OR: 0.13) and 3% (OR: 0.15) of SRCC cases, respectively. In contrast to the 44% rate of APC mts in AC group, only 3% of SRCC patients had APC mts (OR = 0.04). Conclusions: SRCC has distinct molecular features, including low rates of KRAS, PIK3CA and APC mts. Further study to identify activation pathways and potential therapeutic targets are needed.

AB - Background: Signet ring cell carcinoma (SRCC) is a rare subtype of colorectal cancer (CRC). The aim of this study was to characterise the genomic alterations and outcomes of SRCC. Methods: Medical records of metastatic CRC (mCRC) patients whose tumours were evaluated by NGS analysis were reviewed. SC-mCRC were classified into two groups: SRCC (>50% signet ring cells) and adenocarcinoma (AC) with SC component (≤50% signet ring cells). Results: Six hundred and sixty-five mCRC patients were included. Of the 93 mCRC cases with SC features, 63 had slides for review. Of those 63 cases, 35 were confirmed SRCC, and 28 were AC with SC component. Compared with AC group, KRAS and PIK3CA mutations (mts) were found in only 11% (OR: 0.13) and 3% (OR: 0.15) of SRCC cases, respectively. In contrast to the 44% rate of APC mts in AC group, only 3% of SRCC patients had APC mts (OR = 0.04). Conclusions: SRCC has distinct molecular features, including low rates of KRAS, PIK3CA and APC mts. Further study to identify activation pathways and potential therapeutic targets are needed.

UR - http://www.scopus.com/inward/record.url?scp=85070805278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070805278&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0548-9

DO - 10.1038/s41416-019-0548-9

M3 - Article

C2 - 31406299

AN - SCOPUS:85070805278

SN - 0007-0920

VL - 121

SP - 505

EP - 510

JO - British journal of cancer

JF - British journal of cancer

IS - 6

ER -

Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this